|
| Primary information |
|---|
| ID | 16186 |
| Therapeutic ID | Th1699 |
| Protein Name | IR208 |
| Sequence | >Th1699_IR208
MIVCTILVFILANIPCGESLQNELTRCLHNIAMKEFPQEKPLVFSYLWSRYAEEETVSQFSEILMDVRYSIHFEDFLPTLLEVFNELNQSIVVVNNDYNITKSEGPSSFYGGYVILHYVQDDIKLQLVKLVSDSRWNPRANYIVVLIGNIKSNLHKYNVTQNIFSEFWKHNIIQVVVLININLYSRKYEREDEDKIATNVFELYTWYPYKFPGQCAQSYDPILIDRWTTNKSYANFTENRPIFSNKLTRYLNGCHLRISTFESEPVAMCPSGISEEGTLNYDDGLEIRVIKLIQRYTQQSIIYRAPPYHGKWGILLPNGTWTGVLREIIDGSSDIAFGEVYYRCHLEEKIECTISYMYDETNWYVPCAQPIPKWKSLSRVFKISLWIGFITGYIIVSILIWGVVRASNKVAKPGNESTTYINLTNCFTNLWAVILGISATEDIPKKTTIRMVFLLWVMYSLAVNTVYQTFLTSYMIDPGLQHQISSEDELLESNMDYGFVRTLPVLIPDLQAQRYSRKQLCADIEKCIRRMARKKDFAVLHSKYSTDYSAYVRYVDSNGNPLFCHLDETYSRQYVTMSVKKGHLLLGIYNRVIKAVIEGGFYDQWWKELKYLATLRAAANLTVPPGDYIPLSVDHMQSAFYILILGFTVAFNIFIYEVLHKKTLRMRIK
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. |
| Indication/Disease | Investigated for use/treatment in multiple sclerosis. |
| Pharmacodynamics | NA |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |